Thu, November 3, 2022
Wed, November 2, 2022
Tue, November 1, 2022

Brian Abrahams Maintained (BCRX) at Hold with Decreased Target to $13 on, Nov 2nd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-13-on-nov-2nd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Brian Abrahams of RBC Capital, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold with Decreased Target from $14 to $13 on, Nov 2nd, 2022.

Brian has made no other calls on BCRX in the last 4 months.



There are 2 other peers that have a rating on BCRX. Out of the 2 peers that are also analyzing BCRX, all agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Justin Kim of "Oppenheimer" Downgraded from Buy to Hold on, Monday, August 8th, 2022
  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $14 on, Friday, August 5th, 2022

Publication Contributing Sources